128 related articles for article (PubMed ID: 19574481)
1. Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.
Salama ME; Swierczek SI; Hickman K; Wilson A; Prchal JT
Blood; 2009 Jul; 114(1):223-4; author reply 224. PubMed ID: 19574481
[No Abstract] [Full Text] [Related]
2. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).
Hermouet S; Dobo I; Lippert E; Boursier MC; Ergand L; Perrault-Hu F; Pineau D
Leukemia; 2007 May; 21(5):1128-30. PubMed ID: 17301814
[No Abstract] [Full Text] [Related]
3. Higher detection rate of JAK2 mutation using plasma.
Ma W; Kantarjian H; Zhang X; Sun W; Buller AM; Jilani I; Schwartz JG; Giles F; Albitar M
Blood; 2008 Apr; 111(7):3906-7. PubMed ID: 18362222
[No Abstract] [Full Text] [Related]
4. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.
Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; O'Brien S; Giles F; Albitar M
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):95-102. PubMed ID: 19254349
[TBL] [Abstract][Full Text] [Related]
5. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho TL; Mesa R; Gilliland DG; Tefferi A
Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
[No Abstract] [Full Text] [Related]
6. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
7. Clearing the path for MPN therapy monitoring.
Mesa RA
Blood; 2013 Nov; 122(23):3704-5. PubMed ID: 24288406
[No Abstract] [Full Text] [Related]
8. The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders.
Kannim S; Auewarakul CU
Int J Cancer; 2009 Aug; 125(4):988-90. PubMed ID: 19462461
[No Abstract] [Full Text] [Related]
9. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
Malysz J; Crisan D
Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
[TBL] [Abstract][Full Text] [Related]
10. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
11. Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.
Riedlinger G; Hadigol M; Khiabanian H; Ganesan S
JAMA Oncol; 2019 Feb; 5(2):265-267. PubMed ID: 30605212
[TBL] [Abstract][Full Text] [Related]
12. [The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].
Abdullaeva AO; Glinshchikova OA; Suslova SA; Shadieva NKh; Kolosova LIu; Meshcheriakova LM; Vakhrusheva MV; Sudarikov AB
Klin Lab Diagn; 2012 Jul; (7):24-8. PubMed ID: 22988798
[TBL] [Abstract][Full Text] [Related]
13. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
14. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
[TBL] [Abstract][Full Text] [Related]
15. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
16. Clinical implications of JAK2 mutations in myeloproliferative disorders.
Knoops L; Hermans C; Ferrant A; Constantinescu SN
Acta Clin Belg; 2008; 63(2):93-8. PubMed ID: 18575049
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
Kinz E; Muendlein A
Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
19. Quantification of JAK2V617F mutation by next-generation sequencing technology.
Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
[No Abstract] [Full Text] [Related]
20. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.
Vilaine M; Olcaydu D; Harutyunyan A; Bergeman J; Tiab M; Ramée JF; Chen JM; Kralovics R; Hermouet S
Blood; 2011 Dec; 118(24):6468-70. PubMed ID: 22161852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
